{ "schemaVersion": 2, "eyebrow": "Gastroenterology", "title": "Gastroesophageal Reflux Disease", "summary": "Manage GERD by separating unproven reflux from proven reflux with persistent symptoms, selecting ambulatory testing on or off proton pump inhibitors accordingly, and reserving invasive therapy for objectively documented reflux with an appropriate anatomic and physiologic phenotype.", "seoDescription": "Physician guide to GERD diagnosis, reflux monitoring selection, PPI optimization, Barrett screening, and objective selection for antireflux procedures.", "clinicalQuestion": "How should physicians confirm GERD and manage persistent symptoms or consideration of antireflux intervention?", "specialty": "Gastroenterology", "audience": "U.S. physicians and medical trainees", "tags": [ "GERD", "reflux monitoring", "ambulatory pH monitoring", "pH-impedance monitoring", "PPI-refractory GERD", "antireflux surgery", "Barrett esophagus" ], "keyTakeaways": [ "Conclusive GERD evidence includes Los Angeles grade C or D esophagitis, long-segment Barrett mucosa, peptic stricture, or distal esophageal acid exposure time greater than 6% off antisecretory therapy. [2]", "For unproven GERD with persistent symptoms, test off PPI; for previously proven GERD with persistent symptoms despite twice-daily PPI, use pH-impedance monitoring on therapy to identify ongoing reflux burden. [1][2]", "Normal endoscopy plus acid exposure time below 4% and fewer than 40 reflux episodes off PPI supports a non-GERD explanation for symptoms. [2]", "Borderline acid exposure time of 4% to 6% requires integration of symptom association, reflux episode burden, endoscopic findings, and motor/anatomic assessment rather than automatic escalation of acid suppression. [1][2]", "Antireflux procedures should follow objective confirmation of reflux; in incomplete PPI responders with abnormal on-therapy pH-impedance, surgery provided greater symptom relief than continued medical therapy in one randomized trial. [1]" ], "sections": [ { "id": "triage-and-initial-pathway", "eyebrow": "Initial pathway", "heading": "Decide whether GERD is established before labeling symptoms refractory", "intro": "Persistent symptoms require a phenotypic diagnosis, not automatic PPI escalation.", "paragraphs": [ "Begin with EGD with biopsies when symptoms persist after a PPI trial or when alarm features prompt structural and mucosal evaluation. Biopsy during endoscopy is used to exclude alternative mucosal disorders, including eosinophilic and infectious esophagitis. A normal EGD does not exclude GERD, whereas high-grade erosive esophagitis, long-segment Barrett mucosa, or peptic stricture establishes objective evidence of GERD. [2][5]", "Classify the patient as having unproven versus proven GERD before ordering ambulatory reflux testing. Unproven GERD includes persistent symptoms with normal or nondiagnostic endoscopy and no prior abnormal reflux study. Proven GERD includes prior conclusive endoscopic complications or abnormal acid exposure; persistent symptoms in this group may reflect residual reflux, reflux hypersensitivity, motility disease, supragastric belching, rumination, or a nonreflux disorder. [1][2]", "Treat extraesophageal complaints—chronic cough, asthma, laryngitis, or dental erosion—as possible rather than presumptive reflux syndromes. The lower background prevalence of GERD in extraesophageal presentations reduces the diagnostic yield of reflux testing compared with typical symptoms, making objective confirmation particularly important before prolonged escalation of reflux-directed treatment or invasive therapy. [8][24]" ], "bullets": [ "Use EGD with biopsies first when persistent symptoms require exclusion of eosinophilic or infectious esophagitis. [5]", "Do not use a normal EGD alone to rule out GERD. [2]", "Do not infer reflux causality from extraesophageal symptoms alone. [8][24]" ], "subsections": [], "table": { "caption": "Clinical branches that determine the next diagnostic action. [1][2][5]", "columns": [ "Clinical branch", "Key discriminator", "Next action" ], "rows": [ [ "Conclusive GERD", "LA grade C or D esophagitis, long-segment Barrett mucosa, peptic stricture, or off-PPI AET >6% [2]", "Manage as proven GERD; use on-therapy pH-impedance if symptoms persist despite twice-daily PPI and escalation is being considered. [1][2]" ], [ "Unproven GERD", "Normal or nondiagnostic endoscopy without prior objective reflux evidence [2][5]", "Perform ambulatory reflux monitoring off PPI to establish or refute pathologic reflux. [2][5]" ], [ "Persistent extraesophageal symptoms", "Cough, asthma, laryngitis, or dental erosions without established reflux causality [8][24]", "Prioritize objective reflux evaluation and evaluate competing organ-specific diagnoses. [8][24]" ] ] } }, { "id": "ambulatory-reflux-testing", "eyebrow": "Physiologic testing", "heading": "Choose off-PPI versus on-PPI reflux monitoring by the question being asked", "intro": "Testing conditions determine whether the study diagnoses GERD or evaluates treatment failure.", "paragraphs": [ "Use ambulatory reflux monitoring off PPI when the question is whether GERD exists. Withhold antisecretory therapy for at least 7 days before off-therapy monitoring. Catheter pH, wireless pH, and pH-impedance can provide acid-exposure data; the selection depends on availability and cost. Wireless pH monitoring may record for up to 96 hours and is generally better tolerated than a transnasal catheter. [2][5]", "Use pH-impedance monitoring on therapy when GERD is already proven and the question is whether reflux persists despite antisecretory treatment. Impedance detects reflux episodes regardless of acidity, while pH characterizes acidity; therefore, pH-impedance is the preferred modality when monitoring is indicated during PPI therapy. [2]", "Interpret distal esophageal acid exposure time (AET) as a continuum. Off therapy, AET greater than 6% is diagnostic of GERD. AET below 4%, particularly with fewer than 40 reflux episodes and normal endoscopy, supports a non-GERD explanation. AET from 4% to 6% is inconclusive and should be adjudicated with symptom-reflux association and adjunctive endoscopic, motor, and anatomic evidence rather than treated as unequivocal pathologic reflux. [1][2]" ], "bullets": [ "During reflux monitoring, maintain usual meals and activity and record meals, symptoms, and recumbency periods in the diary. [5]", "A positive reflux-symptom association supports reflux-triggered symptoms and may predict a better treatment response. [2]", "Use manometry to define LES location for catheter positioning and to evaluate motor findings when the endoscopic and reflux-monitoring data are inconclusive. [2][5]" ], "subsections": [ { "heading": "Interpret discordant or borderline studies", "paragraphs": [ "Do not equate borderline AET with GERD requiring procedural treatment. In the 4% to 6% range, reflux hypersensitivity, motility disorders, supragastric belching, and rumination may account for symptoms. Even healthy volunteers can show borderline AET across multiday recording, and patients with normal endoscopy or LA grade A esophagitis may overlap with this range. [1]" ], "bullets": [ "If AET is 4% to 6%, review reflux-symptom association, reflux episode count, endoscopic findings, hiatus hernia, and LES/motor assessment before committing to long-term escalation. [1][2]", "If off-PPI AET is below 4% with fewer than 40 reflux episodes and normal endoscopy, redirect evaluation toward non-GERD causes rather than intensifying reflux therapy. [2]" ] } ], "table": { "caption": "Ambulatory reflux monitoring selection and interpretation. [1][2][5]", "columns": [ "Clinical question", "Test condition and modality", "Actionable interpretation" ], "rows": [ [ "Does GERD exist in a patient without prior objective evidence?", "Monitor off PPI after withholding antisecretory therapy for at least 7 days; use catheter pH, wireless pH, or pH-impedance according to availability and cost. [2][5]", "AET >6% supports GERD; AET <4% plus <40 reflux episodes and normal endoscopy supports a non-GERD explanation. [2]" ], [ "Does reflux persist despite therapy in proven GERD?", "Perform pH-impedance monitoring on PPI. [2]", "Persistent abnormal reflux burden can identify patients in whom escalation beyond pharmacotherapy may be reasonable. [1][2]" ], [ "Is the study inconclusive?", "Off-PPI AET 4% to 6%. [1]", "Integrate symptom association, reflux episodes, endoscopic findings, and motor/anatomic data; consider behavioral and motility disorders. [1][2]" ] ] } }, { "id": "medical-management-and-deprescribing", "eyebrow": "Medication strategy", "heading": "Use the lowest PPI dose that controls symptoms or maintains healing", "intro": "Medication intensity should reflect documented disease and symptom response.", "paragraphs": [ "For proven GERD, continue long-term PPI therapy at the lowest dose that provides symptom control and/or healing of reflux-related mucosal injury. When symptoms persist, do not assume pharmacologic failure until objective testing distinguishes ongoing reflux from reflux hypersensitivity, behavioral disorders, or another diagnosis. [15][1][2]", "For patients taking chronic high-intensity PPI therapy without an ongoing indication, use a planned, supervised dose reduction or discontinuation strategy rather than indefinite continuation by default. In GERD patients receiving multiple daily doses, reported success with step-down to once-daily therapy ranged from 42% to 79%; however, recurrent symptoms after discontinuation are expected in chronic GERD because the defective antireflux barrier remains. [3]", "Avoid interpreting a PPI trial as a definitive diagnostic test. In predicting erosive esophagitis or an abnormal pH study, the empiric PPI trial has reported sensitivity of approximately 80% but specificity of only 50% to 60%; persistent or atypical symptoms therefore warrant objective evaluation when the result will alter long-term treatment or procedural decisions. [5]" ], "bullets": [ "Maintain the lowest effective PPI dose for established GERD requiring continued symptom control or healing. [15]", "Consider step-down from multiple-dose PPI therapy when the indication and clinical phenotype permit, with planned reassessment for recurrent symptoms. [3]", "Use objective testing rather than PPI response alone to establish GERD before invasive treatment. [5][2]" ], "subsections": [], "table": { "caption": "Medication decisions linked to diagnostic phenotype. [1][2][3][15]", "columns": [ "Situation", "Medication decision", "Reassessment trigger" ], "rows": [ [ "Proven GERD controlled on PPI", "Continue the lowest dose that controls symptoms and/or maintains healing. [15]", "Reassess if symptom control changes or a dose reduction is clinically appropriate. [15]" ], [ "Multiple-dose PPI without a continuing high-intensity indication", "Use a supervised step-down approach; reported transition to once-daily therapy was successful in 42% to 79% of GERD patients. [3]", "Recurrence after stopping may reflect persistent antireflux-barrier dysfunction. [3]" ], [ "Persistent symptoms with unproven GERD", "Do not escalate solely on symptom persistence or empiric PPI response. [5]", "Obtain off-PPI reflux monitoring to determine whether GERD is present. [2][5]" ] ] } }, { "id": "procedural-selection", "eyebrow": "Escalation", "heading": "Reserve antireflux intervention for objectively documented reflux", "intro": "Procedural benefit depends on confirming reflux burden and matching the intervention to the clinical phenotype.", "paragraphs": [ "Consider antireflux surgery or endoscopic antireflux therapy only after objective reflux documentation, particularly in patients whose symptoms persist despite PPI therapy. In a randomized trial of patients with heartburn incompletely responsive to PPI therapy, abnormal reflux burden on pH-impedance was present in 78 of 366 patients evaluated; among those treated, antireflux surgery produced symptom relief in 67% compared with 28% receiving continued medical management. [1]", "For patients with previously proven GERD studied on twice-daily PPI therapy, AET greater than 4.0% and/or more than 80 reflux episodes identified a group in which 85% reported symptom benefit after antireflux surgery in a separate study. These thresholds apply to an on-therapy, previously proven-GERD population and should not be substituted for off-PPI diagnostic thresholds. [1]", "Before procedural referral, use the physiologic assessment to exclude phenotypes less likely to benefit from further acid-directed intervention: normal off-PPI reflux burden, borderline AET without corroborating evidence, reflux hypersensitivity, motility disorders, supragastric belching, and rumination. The key tradeoff is avoiding an irreversible or invasive intervention for symptoms not driven by pathologic reflux. [1][2]" ], "bullets": [ "Objective reflux documentation is a prerequisite for escalation beyond medication in persistent symptoms. [1][2]", "In proven GERD with symptoms despite twice-daily PPI, obtain on-therapy pH-impedance rather than an off-therapy study when deciding whether residual reflux supports escalation. [1][2]", "Use endoscopic, reflux-monitoring, motor, and anatomic data together when results are borderline or discordant. [1][2]" ], "subsections": [], "table": { "caption": "Objective findings that support or argue against invasive reflux therapy. [1][2]", "columns": [ "Finding", "Implication", "Next step" ], "rows": [ [ "Off-PPI AET >6% or conclusive endoscopic complication", "GERD is objectively established. [2]", "If symptoms remain burdensome, assess whether reflux persists on treatment and whether antireflux intervention fits the full physiologic and anatomic profile. [1][2]" ], [ "Previously proven GERD on twice-daily PPI with AET >4% and/or >80 reflux episodes", "Persistent on-therapy reflux burden may identify patients likely to benefit from antireflux surgery. [1]", "Discuss procedural escalation after multidisciplinary physiologic and anatomic assessment. [1][2]" ], [ "Normal endoscopy, off-PPI AET <4%, and <40 reflux episodes", "This combination supports a non-GERD explanation. [2]", "Avoid reflux-directed procedural escalation; evaluate alternative symptom mechanisms. [1][2]" ] ] } }, { "id": "barrett-risk-and-pathology", "eyebrow": "Complications", "heading": "Screen selected chronic GERD patients for Barrett esophagus and verify dysplasia", "intro": "Endoscopic screening is risk-based, and dysplasia changes the treatment pathway.", "paragraphs": [ "Consider Barrett esophagus screening in patients with chronic GERD symptoms plus at least three additional risk factors: male sex, age older than 50 years, White race, current or prior tobacco smoking, central obesity, or a first-degree family history of Barrett esophagus or esophageal adenocarcinoma. [18]", "When Barrett-associated dysplasia is diagnosed, obtain confirmation by a second expert gastrointestinal pathologist because the diagnosis materially changes surveillance and treatment decisions. Endoscopic eradication therapy is used for low-grade dysplasia, high-grade dysplasia, and early esophageal adenocarcinoma and is preferred to surveillance and acid suppression alone for these neoplastic stages. [18]", "Do not use antireflux procedures as a substitute for Barrett surveillance or dysplasia-directed care. Current Barrett surveillance guidance specifically addresses the role of antireflux procedures in prevention of progression, alongside surveillance methods, sampling strategies, biomarkers, and chemoprevention. [19]" ], "bullets": [ "Screen chronic GERD patients only when the specified cumulative Barrett risk profile is present. [18]", "Confirm Barrett dysplasia with a second expert pathologist before committing to eradication or surveillance pathways. [18]", "Refer low-grade dysplasia, high-grade dysplasia, and early adenocarcinoma for endoscopic eradication therapy evaluation. [18]" ], "subsections": [], "table": { "caption": "Barrett esophagus decisions that alter management. [18][19]", "columns": [ "Finding", "Required confirmation or risk criterion", "Management consequence" ], "rows": [ [ "Chronic GERD symptoms", "At least three additional risk factors: male sex, age >50 years, White race, tobacco exposure, central obesity, or first-degree family history of Barrett esophagus or esophageal adenocarcinoma. [18]", "Consider screening endoscopy for Barrett esophagus. [18]" ], [ "Barrett-associated dysplasia", "Second expert pathologist confirmation. [18]", "Direct low-grade dysplasia, high-grade dysplasia, and early adenocarcinoma toward endoscopic eradication therapy evaluation. [18]" ], [ "Barrett esophagus under surveillance", "Use a surveillance pathway that addresses imaging, sampling, risk stratification, and therapy decisions. [19]", "Do not substitute an antireflux procedure for dysplasia-specific surveillance or treatment decisions. [19]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Updates to the modern diagnosis of GERD: Lyon ...", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/73/2/361", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 2, "title": "Modern diagnosis of GERD: the Lyon Consensus", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/early/2018/02/03/gutjnl-2017-314722.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 3, "title": "Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients | BMJ Open", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/16/4/e101266", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com" }, { "number": 4, "title": "Minimally invasive endoscopic therapies for gastro- ...", "detail": "fg.bmj.com", "url": "https://fg.bmj.com/content/14/3/249", "authors": "fg.bmj.com", "host": "fg.bmj.com" }, { "number": 5, "title": "Advances in the physiological assessment and diagnosis of GERD | Nature Reviews Gastroenterology & Hepatology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/nrgastro.2017.130", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 6, "title": "Gastroesophageal reflux monitoring: pH and impedance : GI Motility online", "detail": "www.nature.com", "url": "https://www.nature.com/gimo/contents/pt1/full/gimo31.html", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 7, "title": "Piloting an intraoral pH device to track gastroesophageal ...", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-024-68748-2", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 8, "title": "ACG Practice Guidelines : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/abstract/00000434-200703000-00031~acg-practice-guidelines-esophageal-reflux-testing", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 9, "title": "Gastroesophageal reflux disease: comprehensive... : International Journal of Surgery", "detail": "journals.lww.com", "url": "https://journals.lww.com/international-journal-of-surgery/fulltext/2026/03000/gastroesophageal_reflux_disease__comprehensive.180.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 10, "title": "Letter to the Editor in Response to ACG Guidelines ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/2022/12000/letter_to_the_editor_in_response_to_acg_guidelines.35.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 11, "title": "Chinese expert consensus on diagnosis and management ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/agm2.12293", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 12, "title": "Editorial:Diagnostic Testing in Extraesophageal... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/abstract/10.1038/ajg.2013.80~editorialdiagnostic-testing-in-extraesophageal-gerd-another", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 13, "title": "An insight into gastroesophageal reflux disease and its ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/rpsppr/article/4/2/rqaf001/7964693", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 14, "title": "UCSD Human Research Protections Program", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/11/NCT03619811/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov" }, { "number": 15, "title": "Management of Gastroesophageal Reflux Disease", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(17)35989-9/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 16, "title": "Long-term Outcomes of Patients Receiving a Magnetic ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S1542-3565(15)00763-6/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 17, "title": "Efficacy of Transoral Fundoplication vs Omeprazole for ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/s0016-5085(14)01208-6/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 18, "title": "Barrett Esophagus - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK430979", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 19, "title": "AGA Clinical Practice Guideline on Surveillance of Barrett's ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(25)06013-5/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 20, "title": "Current Management Practices for... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/00000434-201210001-01487~current-management-practices-for-moderate-to-severe", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 21, "title": "Reflux Monitoring: On or Off Therapy? : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/pdf/10.1038/ajg.2010.318~reflux-monitoring-on-or-off-therapy", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 22, "title": "S985 Certified Medical Education Leads to Changes... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/10.14309/01.ajg.0001131400.83917.b2~s985certified-medical-education-leads-to-changes-in-clinical", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 23, "title": "Diagnostic accuracy of gastroesophageal reflux... : Neurogastroenterology & Motility", "detail": "journals.lww.com", "url": "https://journals.lww.com/00043897-202312000-00016", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 24, "title": "The Montreal Definition and Classification of... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/abstract/00000434-200608000-00033~the-montreal-definition-and-classification-of", "authors": "journals.lww.com", "host": "journals.lww.com" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Updates to the modern diagnosis of GERD: Lyon ...", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/73/2/361", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "When AET is between 4.0% and 6.0%, further clinical context and additional test data are needed to determine the need for GERD management,1 since other conditions including reflux hypersensitivity, motility disorders and behavioural disorders such as supragastric belching and rumination may be contr", "score": 0.6964752 }, { "number": 2, "title": "Modern diagnosis of GERD: the Lyon Consensus", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/gutjnl/early/2018/02/03/gutjnl-2017-314722.full.pdf", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "grades C and D), long-segment Barrett’s mucosa or peptic strictures on endoscopy or distal oesophageal acid exposure time (AET) >6% on ambulatory pH or pH-impedance monitoring. A normal endoscopy does not exclude GERD, but provides supportive evidence refuting GERD in conjunction with distal AET <4%", "score": 0.6609831 }, { "number": 3, "title": "Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients | BMJ Open", "detail": "bmjopen.bmj.com", "url": "https://bmjopen.bmj.com/content/16/4/e101266", "authors": "bmjopen.bmj.com", "host": "bmjopen.bmj.com", "snippet": "Since their launch in 1989, proton pump inhibitors (PPIs) have caused a paradigm shift in the treatment of peptic ulcers and gastro-oesophageal reflux disease (GERD). Clinicians and patients have rapidly embraced PPIs, perceived as efficacious and safe, resulting in steadily rising prescriptions and", "score": 0.4765072 }, { "number": 4, "title": "Minimally invasive endoscopic therapies for gastro- ...", "detail": "fg.bmj.com", "url": "https://fg.bmj.com/content/14/3/249", "authors": "fg.bmj.com", "host": "fg.bmj.com", "snippet": "by N Aslam · 2023 · Cited by 10 — Transoral incisionless fundoplication with an ultrasonic surgical endostapler for the treatment of gastroesophageal reflux disease: 12-month outcomes.", "score": 0.3953682 }, { "number": 5, "title": "Advances in the physiological assessment and diagnosis of GERD | Nature Reviews Gastroenterology & Hepatology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/nrgastro.2017.130", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Data acquisition. Catheter-based ambulatory reflux monitoring (pH or pH-impedance studies) is performed over a 24 h period, with the distal oesophageal pH sensor positioned 5 cm proximal to the manometrically measured LES. Wireless pH probes are typically positioned 6 cm proximal to the squamocolumn", "score": 0.63939893 }, { "number": 6, "title": "Gastroesophageal reflux monitoring: pH and impedance : GI Motility online", "detail": "www.nature.com", "url": "https://www.nature.com/gimo/contents/pt1/full/gimo31.html", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Key Points\n Introduction\n Esophageal pH Monitoring\n Figure 1: Ambulatory pH catheter placement.\n Figure 2: Catheter free pH monitoring system (Bravo system).\n Figure 3: Reflux episode identified by pH monitoring as a rapid drop in pH from above to below 4.0 distally longer than proximal.\n Table 1: N", "score": 0.55362654 }, { "number": 7, "title": "Piloting an intraoral pH device to track gastroesophageal ...", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41598-024-68748-2", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "by S Hu · 2024 · Cited by 1 — The development of an intraoral pH monitor can provide a less invasive study to aid in the diagnosis and management of GERD.", "score": 0.25138617 }, { "number": 8, "title": "ACG Practice Guidelines : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/abstract/00000434-200703000-00031~acg-practice-guidelines-esophageal-reflux-testing", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Reconciling these disparate data, three general observations can be made regarding the utility of pH testing on-therapy for patients presenting with refractory reflux symptoms. First, ongoing abnormal esophageal acid exposure frequently occurs in patients with refractory typical or atypical reflux s", "score": 0.7355091 }, { "number": 9, "title": "Gastroesophageal reflux disease: comprehensive... : International Journal of Surgery", "detail": "journals.lww.com", "url": "https://journals.lww.com/international-journal-of-surgery/fulltext/2026/03000/gastroesophageal_reflux_disease__comprehensive.180.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Widnicka-Siergiejko AK, Marek T, W-sko-czopnik D, et al. GERD diagnostic and therapeutic consensus by the polish society of gastroenterology. Pol Arch Intern Med 2022;132:16196.Cited HereGoogle Scholar \n ## \n\nHelm JF. Esophageal acid clearance. J Clin Gastroenterol 1986;8:5–11.Cited HereFull TextC", "score": 0.69795954 }, { "number": 10, "title": "Letter to the Editor in Response to ACG Guidelines ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/2022/12000/letter_to_the_editor_in_response_to_acg_guidelines.35.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "by M Haseeb · 2022 · Cited by 2 — In conclusion, this guideline provides practical recommendations for the evaluation and management of gastroesophageal reflux disease, and we sincerely", "score": 0.6191726 }, { "number": 11, "title": "Chinese expert consensus on diagnosis and management ...", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/agm2.12293", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "by L Fangxu · 2024 · Cited by 13 — Heartburn and reflux are common and typical symptoms of GERD. Heartburn refers to a burning sensation in the posterior sternum, while reflux", "score": 0.51105833 }, { "number": 12, "title": "Editorial:Diagnostic Testing in Extraesophageal... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/abstract/10.1038/ajg.2013.80~editorialdiagnostic-testing-in-extraesophageal-gerd-another", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Proton pump inhibitors (PPIs) work for most patients with gastroesophageal reflux disease (GERD). But when PPIs fail to work, or when there are atypical extra-esophageal symptoms, diagnostic and management decisions become much more difficult. Although atypical GERD is common, there are limited data", "score": 0.4617697 }, { "number": 13, "title": "An insight into gastroesophageal reflux disease and its ...", "detail": "academic.oup.com", "url": "https://academic.oup.com/rpsppr/article/4/2/rqaf001/7964693", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "One noninvasive diagnostic method for GERD is the PPI test, sometimes referred to as a brief treatment trial. ... Endoscopy is advised following PPI treatment", "score": 0.45536873 }, { "number": 14, "title": "UCSD Human Research Protections Program", "detail": "cdn.clinicaltrials.gov", "url": "https://cdn.clinicaltrials.gov/large-docs/11/NCT03619811/Prot_SAP_000.pdf", "authors": "cdn.clinicaltrials.gov", "host": "cdn.clinicaltrials.gov", "snippet": "reflux. JAMA 2005;294:1534-40. 28. Naik RD, Vaezi MF. Extra-esophageal manifestations of GERD: who responds to GERD therapy? Curr Gastroenterol Rep 2013;15:318. 29. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice 2002;16:274-7. 30. Agrawal N, Y", "score": 0.3410561 }, { "number": 15, "title": "Management of Gastroesophageal Reflux Disease", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(17)35989-9/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "by CP Gyawali · 2018 · Cited by 468 — Best practice recommendations for proven GERD consist of long-term therapy with the lowest dose of PPI that provides symptom control and/or healing of", "score": 0.4630806 }, { "number": 16, "title": "Long-term Outcomes of Patients Receiving a Magnetic ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S1542-3565(15)00763-6/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "by RA Ganz · 2016 · Cited by 254 — Transoral incisionless fundoplication 2.0 procedure using EsophyXTM for gastroesophageal reflux disease", "score": 0.3269485 }, { "number": 17, "title": "Efficacy of Transoral Fundoplication vs Omeprazole for ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/s0016-5085(14)01208-6/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "by JG Hunter · 2015 · Cited by 284 — Transoral esophagogastric fundoplication (TF) can decrease or eliminate features of gastroesophageal reflux disease (GERD) in some patients", "score": 0.29396713 }, { "number": 18, "title": "Barrett Esophagus - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK430979", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "In 2022, the American College of Gastroenterology (ACG) published new clinical guidelines for diagnosing and managing Barrett esophagus. No randomized controlled trials have confirmed that screening patients with Barrett esophagus reduces mortality from esophageal adenocarcinoma; screening, endoscop", "score": 0.796562 }, { "number": 19, "title": "AGA Clinical Practice Guideline on Surveillance of Barrett's ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(25)06013-5/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "Crossref\n\nScopus (487)\n\nPubMed\n\nGoogle Scholar\n\n Development of this guideline was wholly funded by the AGA Institute with no support from the industry. A full list of conflicts can be accessed at the AGA’s National Office in Bethesda, MD.\n\n### Scope\n\nThe guideline panel and evidence review team for", "score": 0.76701033 }, { "number": 20, "title": "Current Management Practices for... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/00000434-201210001-01487~current-management-practices-for-moderate-to-severe", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Journals\n\n# Current Management Practices for Moderate-To-Severe Gastroesophageal Reflux Disease (GERD) in Canadian Primary Care Practice\n\n## 1487\n\n## Article Level Metrics\n\n## Related Articles\n\n## Readers Of this Article Also Read\n\n## Most Popular Articles\n\nwk-lippincott-logo\nprivacy policy options", "score": 0.3399377 }, { "number": 21, "title": "Reflux Monitoring: On or Off Therapy? : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/pdf/10.1038/ajg.2010.318~reflux-monitoring-on-or-off-therapy", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "The role of esophageal pH (or impedance) monitoring in diagnosing gastroesophageal reflux disease (GERD) has evolved over the years. In the era of empiric therapy with potent acid-suppressive agents such as proton pump inhibitors (PPIs), esophageal reflux monitoring is often reserved for patients wi", "score": 0.29263115 }, { "number": 22, "title": "S985 Certified Medical Education Leads to Changes... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/fulltext/10.14309/01.ajg.0001131400.83917.b2~s985certified-medical-education-leads-to-changes-in-clinical", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Journals\n\nCrossmark: Check for updates\n\n# S985 Certified Medical Education Leads to Changes in Clinical Practice Regarding Management of Gastroesophageal Reflux Disease\n\n## Article Level Metrics\n\n## Related Articles\n\n## Readers Of this Article Also Read\n\n## Most Popular Articles\n\nwk-lippincott-logo\n", "score": 0.27426437 }, { "number": 23, "title": "Diagnostic accuracy of gastroesophageal reflux... : Neurogastroenterology & Motility", "detail": "journals.lww.com", "url": "https://journals.lww.com/00043897-202312000-00016", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Crossmark: Check for updates\n\n# Diagnostic accuracy of gastroesophageal reflux disease questionnaire for gastroesophageal reflux disease\n\n## A systematic review and meta‐analysis\n\n## Related Articles\n\n## Readers Of this Article Also Read\n\n## Most Popular\n\nwk-ovid-logo\nprivacy policy options", "score": 0.26742655 }, { "number": 24, "title": "The Montreal Definition and Classification of... : American Journal of Gastroenterology", "detail": "journals.lww.com", "url": "https://journals.lww.com/ajg/abstract/00000434-200608000-00033~the-montreal-definition-and-classification-of", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "The level of agreement strengthened throughout the process with two-thirds of the participants agreeing with 86%, 88%, 94%, and 100% of statements at each vote, respectively. At the final vote, 94% of the final 51 statements were approved by 90% of the Consensus Group, and 90% of statements were acc", "score": 0.2579968 } ], "publishedAt": "2026-08-21T02:10:59.514195+00:00", "updatedAt": "2026-08-21T02:10:59.514195+00:00", "readingMinutes": 6, "slug": "gastroesophageal-reflux-disease" }